| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
674,040,000 |
| Market
Cap: |
16.30(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$17.15 - $26.07 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Avantor is a global manufacturer and distributor that provides products and services to customers in the biopharmaceutical, healthcare, education and government and advanced technologies and applied materials industries. Co.'s portfolio includes: Materials and consumables, such as lab products and supplies, formulated silicone materials, customized excipients, and customized single-use assemblies; equipment and instrumentation, such as filtration systems, virus inactivation systems, and incubators; and services and specialty procurement, such as onsite lab and production, clinical, equipment, procurement and sourcing and biopharmaceutical material scale-up and development services.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
27,500 |
| Total Buy Value |
$0 |
$0 |
$0 |
$573,100 |
| Total People Bought |
0 |
0 |
0 |
2 |
| Total Buy Transactions |
0 |
0 |
0 |
2 |
| Total Shares Sold |
27,872 |
27,872 |
60,449 |
143,821 |
| Total Sell Value |
$687,456 |
$687,456 |
$1,380,595 |
$3,696,863 |
| Total People Sold |
3 |
3 |
4 |
5 |
| Total Sell Transactions |
4 |
4 |
6 |
14 |
| End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Vanderhaegen Frederic |
EVP, Europe |
• – – |
2021-02-22 |
4 |
D |
$28.69 |
$11,419 |
D/D |
(398) |
237,388 |
|
- |
|
| Couturier Christophe |
EVP, Services |
• – – |
2021-02-22 |
4 |
D |
$28.69 |
$37,670 |
D/D |
(1,313) |
162,408 |
|
- |
|
| Wondrasch Michael |
EVP & CIO |
• – – |
2021-02-05 |
4 |
S |
$29.77 |
$1,472,662 |
D/D |
(49,468) |
141,543 |
|
-17% |
|
| Wondrasch Michael |
EVP & CIO |
• – – |
2021-02-05 |
4 |
OE |
$23.20 |
$928,000 |
D/D |
40,000 |
181,543 |
|
- |
|
| Murray Mark Christopher |
EVP, Biomaterials & AT |
• – – |
2021-01-13 |
4 |
D |
$29.20 |
$26,806 |
D/D |
(918) |
11,458 |
|
- |
|
| Bramwell James |
EVP, Strategic Partners |
• – – |
2021-01-11 |
4 |
AS |
$30.00 |
$75,150 |
D/D |
(2,505) |
116,430 |
|
2% |
|
| Brophy Gerard |
EVP, Biopharma Production |
• – – |
2021-01-11 |
4 |
AS |
$30.04 |
$11,381,196 |
D/D |
(378,580) |
178,515 |
|
2% |
|
| Brophy Gerard |
EVP, Biopharma Production |
• – – |
2021-01-11 |
4 |
OE |
$23.20 |
$8,783,056 |
D/D |
378,580 |
340,763 |
|
- |
|
| Brophy Gerard |
EVP, Biopharma Production |
• – – |
2021-01-06 |
4 |
AS |
$27.24 |
$313,505 |
D/D |
(11,509) |
178,515 |
|
10% |
|
| Brophy Gerard |
EVP, Biopharma Production |
• – – |
2021-01-04 |
4 |
AS |
$27.84 |
$1,654,197 |
D/D |
(59,418) |
190,024 |
|
11% |
|
| Brophy Gerard |
EVP, Biopharma Production |
• – – |
2021-01-04 |
4 |
OE |
$18.45 |
$1,096,262 |
D/D |
59,418 |
249,442 |
|
- |
|
| Wondrasch Michael |
EVP & CIO |
• – – |
2021-01-02 |
4 |
D |
$28.15 |
$114,936 |
D/D |
(4,083) |
149,974 |
|
- |
|
| Brophy Gerard |
EVP, Biopharma Production |
• – – |
2021-01-02 |
4 |
D |
$28.15 |
$184,636 |
D/D |
(6,559) |
190,024 |
|
- |
|
| Szlosek Thomas A |
EVP & CFO |
• – – |
2021-01-02 |
4 |
D |
$28.15 |
$229,000 |
D/D |
(8,135) |
257,999 |
|
- |
|
| Vanderhaegen Frederic |
EVP, Europe |
• – – |
2021-01-02 |
4 |
D |
$28.15 |
$28,629 |
D/D |
(1,017) |
236,414 |
|
- |
|
| Henson Meghan |
EVP, Chief HR Officer |
• – – |
2020-12-31 |
4 |
A |
$0.00 |
$0 |
D/D |
17,762 |
17,762 |
|
- |
|
| Lewis Sheri |
EVP, Global Ops & Supply Chain |
• – – |
2020-12-31 |
4 |
A |
$0.00 |
$0 |
D/D |
53,286 |
53,286 |
|
- |
|
| Eck Steven W |
SVP & Chief Accounting Officer |
• – – |
2020-12-31 |
4 |
D |
$28.15 |
$85,914 |
D/D |
(3,052) |
20,431 |
|
- |
|
| Bramwell James |
EVP, Strategic Partners |
• – – |
2020-12-21 |
4 |
AS |
$27.14 |
$271,943 |
D/D |
(10,020) |
117,768 |
|
15% |
|
| Shaw Christi |
Director |
– • – |
2020-12-11 |
4 |
S |
$26.68 |
$381,150 |
D/D |
(14,286) |
11,319 |
|
-23% |
|
| Stubblefield Michael |
President and CEO |
• • – |
2020-12-11 |
4 |
GA |
$0.00 |
$0 |
I/I |
400,000 |
400,000 |
|
- |
|
| Stubblefield Michael |
President and CEO |
• • – |
2020-12-11 |
4 |
GD |
$0.00 |
$0 |
D/D |
400,000 |
1,447,265 |
|
- |
|
| Stubblefield Michael |
President and CEO |
• • – |
2020-12-07 |
4 |
AS |
$27.45 |
$2,702,507 |
D/D |
(98,452) |
1,847,265 |
|
16% |
|
| Stubblefield Michael |
President and CEO |
• • – |
2020-12-07 |
4 |
OE |
$1.60 |
$336,590 |
D/D |
210,369 |
1,945,717 |
|
- |
|
| Stubblefield Michael |
President and CEO |
• • – |
2020-12-04 |
4 |
AS |
$27.08 |
$11,162,051 |
D/D |
(412,188) |
1,735,348 |
|
19% |
|
542 Records found
|
|
Page 14 of 22 |
|
|
0.60 (2.42%) 
